

A33432 (070050.1354)
Express Mail No. ED291601158US
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Modak *et al.*

Appln. No.: 09/746,670

Examiner : Rachel M. Bennett

Filed : December 22, 2000

Group Art Unit: 1615

For : ANTIMICROBIAL MEDICAL DEVICES

Customer No. : 21003

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


I hereby certify that this paper is being deposited with the United States Postal Service as Express Mail in an envelope addressed to: Commissioner for Patents, Box 1450, Alexandria, VA 22313-1450.

March 14, 2005

Date of Deposit

Peter J. Shen

Attorney Name


Signature

52,217

Patent Reg. No.

March 14, 2005

Date of Signature

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In further supplement to the Information Disclosure Statement filed on October 28, 2002 and the supplemental Information Disclosure Statements filed on July 9, 2003 and November 11, 2003, and pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants respectfully request that the information presented in this Supplemental Information Disclosure Statement and on the

accompanying PTO Form PTO 1449 be considered by the Examiner and made of record in the above-captioned application.

The following information is presented by Applicants:

On April 17, 2000, which is prior to the December 22, 2000 filing date of the present application (Serial No. 09/746,670), a triple lumen catheter was sold by the licensee, Arrow Incorporated, in the United States. This catheter had an outer coating prepared using a solution containing three percent (3%) weight by volume (w/v) of chlorhexidine diacetate and 0.75 percent w/v silver sulfadiazine. The catheter had an inner lumen coating prepared using a solution containing the solvent ethanol, 0.75 percent (0.75%) w/v chlorhexidine free base, and 0.75 percent (0.75%) w/v chlorhexidine diacetate.

The submission of this Supplemental Information Disclosure Statement does not constitute an admission that any information presented herein is material or constitutes "prior art." Indeed, Applicants reserve the right to show to the U.S. Patent and Trademark Office that the pending claims are patentable under United States law in view of information presented herein.

This Supplemental Information Disclosure Statement is being filed together with a Request for Continued Examination in lieu of payment of the Issue Fee, which is due today. As the required fee for the Request for Continued Examination is submitted herewith, no additional fee is believed to be due for the submission of this Supplemental Information Disclosure

Statement. Should any additional fee be required, however, the Commissioner is authorized to charge any such fee to Deposit Account No. 02-4377.

Respectfully submitted,

BAKER BOTTS L.L.P.



Lisa B. Kole
Patent Office Reg. No. 35,225

Peter J. Shen
Patent Office Reg. No. 52,217

30 Rockefeller Plaza
New York, NY 10012-4498

Attorney for Applicants
212-408-2500

Enclosure

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.
A33432 (070050.1354)

Serial No.
09/746,670

***SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT, BY APPLICANTS**

Applicants
Modak *et al.*

Filing Date
December 22, 2000

Group Art Unit
1615

U.S. PATENT DOCUMENTS

*Exam. Init.		Document No.	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENT

		Document No.	Date	Country	Class	SubClass	Translator	
							Yes	No

OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

			On April 17, 2000, which is prior to the December 22, 2000 filing date of the present application (Serial No. 09/746,670), a triple lumen catheter was sold by the licensee, Arrow Incorporated, in the United States. This catheter had an outer coating prepared using a solution containing three percent (3%) weight by volume (w/v) of chlorhexidine diacetate and 0.75 percent w/v silver sulfadiazine. The catheter had an inner lumen coating prepared using a solution containing the solvent ethanol, 0.75 percent (0.75%) w/v chlorhexidine free base, and 0.75 percent (0.75%) w/v chlorhexidine diacetate.

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

NY02:514696.1